Comparision between patients with or without multilineage dysplasia (MLD) concerning overall survival (A+C) and eventfree survival (B+D) in patients ≤ 60 years with de novo AML (A+B) and in patients without t(8;21), inv(16), t(16;16), t(15;17) and (11q23) abnormalities according to the WHO classification (C+D).